Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination

Clinical Cancer Research

Volumn 17, Issue 13, 2011, Pages 4541-4549

  Mulder, Sasja F ^a   Jacobs, Joannes F M ^a   Olde Nordkamp, Michel A M ^a   Galama, Joep M D ^a   Desar, Ingrid M E ^a   Torensma, Ruurd ^a   Teerenstra, Steven ^a   Mulders, Peter F A ^a   Vissers, Kris C P ^a   Punt, Cornelis J A ^a   De Vries, I Jolanda M ^a   Van Herpen, Carla M L ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; INFLUENZA VACCINE; SORAFENIB; SUNITINIB;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; INFLUENZA VACCINATION; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SEASONAL INFLUENZA; VIRUS STRAIN;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INDOLES; INFLUENZA VACCINES; INFLUENZA, HUMAN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; PYRROLES; TIME FACTORS; VACCINATION;

EID: 79960319572     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0253     Document Type: Article

References (40)

1. Kavanaugh DY, Carbone DP. Immunologic dysfunction in cancer. Hematol Oncol Clin North Am 1996;10:927-51. (Pubitemid 26240366)
2. Finke J, Ferrone S, Frey A, Mufson A, Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today 1999;20:158-60. (Pubitemid 29172275)
3. Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000;164:1269-76. (Pubitemid 30067239)
4. Uzzo RG, Rayman P, Kolenko V, Clark PE, Bloom T, Ward AM, et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res 1999;5:1219-29. (Pubitemid 29233241)
5. Griffiths RW, Elkord E, Gilham DE, Ramani V, Clarke N, Stern PL, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007;56:1743-53. (Pubitemid 47313079)
6. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82.
7. Gigante M, Blasi A, Loverre A, Mancini V, Battaglia M, Selvaggi FP, et al. Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anticancer vaccine. Mol Immunol 2009;46:893-901.
8. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 1998;4:585-93. (Pubitemid 28193556)
9. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998;10:588-94. (Pubitemid 28479193)
10. Onishi T, Ohishi Y, Imagawa K, Ohmoto Y, Murata K. An assessment of the immunological environment based on intratumoral cytokine production in renal cell carcinoma. BJU Int 1999;83:488-92. (Pubitemid 29151178)
11. Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J, et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 2009;100:1111-9.
12. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-103. (Pubitemid 26338628)
13. Ohm JE, Gabrilovich DI, Sempowski GD, Kisseleva E, Parman KS, Nadaf S, et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003;101:4878-86. (Pubitemid 36857749)
14. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010;70:6171-80.
15. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109. (Pubitemid 39331023)
16. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24. (Pubitemid 46630489)
17. Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008;111:5610-20.
18. Zhao W, Gu YH, Song R, Qu BQ, Xu Q. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia 2008;22:1226-33. (Pubitemid 351833791)
19. Gu Y, Zhao W, Meng F, Qu B, Zhu X, Sun Y, et al. Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice. Clin Immunol 2010;135:55-62.
20. + dendritic cell frequency predicts progression-free survival. Clin Cancer Res 2008;14:5884-92.
21. Krusch M, Salih J, Schlicke M, Baessler T, Kampa KM, Mayer F, et al. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J Immunol 2009;183:8286-94.
22. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009;69:2514-22.
23. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148-57.
24. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
25. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34. (Pubitemid 46089673)
26. Demetri GD, Van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38. (Pubitemid 44528723)
27. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-19.
28. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300. (Pubitemid 46630787)
29. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-associated hospitalizations in the United States. JAMA 2004;292:1333-40. (Pubitemid 39223224)
30. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-86. (Pubitemid 36068705)
31. Pollyea DA, Brown JM, Horning SJ. Utility of influenza vaccination for oncology patients. J Clin Oncol 2010;28:2481-90.
32. Cooksley CD, Avritscher EB, Bekele BN, Rolston KV, Geraci JM, Elting LS. Epidemiology and outcomes of serious influenza-related infections in the cancer population. Cancer 2005;104:618-28. (Pubitemid 41022821)
33. Vilar-Compte D, Cornejo P, Valle-Salinas A, Roldan-Marin R, Iguala M, Cervantes Y, et al. Influenza vaccination in patients with breast cancer: a case-series analysis. Med Sci Monit 2006;12:CR332-6.
34. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009;9:493-504.
35. Ring A, Marx G, Steer C, Harper P. Influenza vaccination and chemotherapy: a shot in the dark?Support Care Cancer 2002;10:462-465.
36. Brydak LB, Machala M. Humoral immune response to influenza vaccination in patients from high risk groups. Drugs 2000;60:35-53. (Pubitemid 30601315)
37. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008.MMWRRecomm Rep 2008;57:1-60.
38. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003;115:63-73.
39. Gijzen K, Liu WM, Visontai I, Oftung F, Van Der WS, Korsvold GE, et al. Standardization and validation of assays determining cellular immune responses against influenza. Vaccine 2010;28:3416-22.
40. Mainiero F, Gismondi A, Soriani A, Cippitelli M, Palmieri G, Jacobelli J, et al. Integrin-mediated ras-extracellular regulated kinase (ERK) signaling regulates interferon gamma production in human natural killer cells. J Exp Med 1998;188:1267-75. (Pubitemid 28478015)